D
Danielle Ouellet
Researcher at GlaxoSmithKline
Publications - 1
Citations - 63
Danielle Ouellet is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Multicenter trial & Dabrafenib. The author has an hindex of 1, co-authored 1 publications receiving 61 citations.
Papers
More filters
Journal ArticleDOI
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Anne-Marie Martin,Danielle Ouellet,Kelly M. Grotzinger,Vicki L. Goodman,Paul B. Chapman +16 more
TL;DR: Dabrafenib demonstrated a significant improvement in PFS and ORR over DTIC with an acceptable safety profile and benefits in P FS and RR were observed in all subgroups evaluated.